• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by TC BioPharm (Holdings) plc

    12/16/24 4:05:16 PM ET
    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TCBP alert in real time by email
    6-K 1 form6-k.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of December 2024

     

    Commission File Number 001-41231

     

    TC BIOPHARM (HOLDINGS) PLC

    (Translation of registrant’s name into English)

     

     

    Maxim 1, 2 Parklands Way

    Holytown, Motherwell, ML1 4WR

    Scotland, United Kingdom

    +44 (0) 141 433 7557

     

     

    (Address of Principal Executive Offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

      ☒ Form 20-F ☐ Form 40-F  

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____ ☐

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____ ☐

     

     

     

     

     

     

    Notice, Proxy Statement and Proxy Card for General Meeting

     

    TC BioPharm (Holdings) PLC (the “Company”) hereby publishes notice (“Notice”) of a general meeting of shareholders (the “Meeting”), which is scheduled to take place at 2:00 p.m. (UK time) on Monday, December 30, 2024, at The Seafield Arms Hotel, 17-19 Seafield St, Cullen, Buckie AB56 4SH, Scotland, United Kingdom.

     

    Shareholders of record as of 2:00 p.m. (UK time) on December 24, 2024 are entitled to vote at the Meeting. The Company’s holders of American Depositary Shares (the “ADS Holders”) are not shareholders of record, but, under the terms of the Depositary Agreement between the Company, the Depositary and the ADS Holders, they will be able to vote by proxy ahead of the meeting, before 12:00 p.m. Eastern Standard Time on December 24, 2024, in accordance with separate instructions which will be issued by the Depositary.

     

    Attached as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) is the Notice of 2024 General Meeting of Shareholders, which contains information concerning the agenda for the Meeting, background for the proposals at the Meeting, the voting procedure and additional general matters related to the Meeting.

     

    Attached as Exhibit 99.2 to this Form 6-K is the form of proxy card being distributed by the Company to its shareholders of record as of the record date for the Meeting, which serves as the primary means for those shareholders to cast their votes on the proposals to be presented at the Meeting.

     

    Attached as Exhibit 99.3 to this Form 6-K is the form of proxy card being distributed by the Depositary to ADS Holders of record as of December 9, 2024, which serves as the primary means for those ADS Holders to cast their votes on the proposals to be presented at the Meeting.

     

    INDEX TO EXHIBITS

     

    Number   Description
    99.1   Notice of General Meeting.
    99.2   Form of Proxy for the Depositary.
    99.3   Voting Instruction Form for holders of American Depositary Shares.

     

    2/3

     

     

    Signature

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      TC BIOPHARM (HOLDINGS) PLC
         
      By: /s/ Martin Thorp
      Name: Martin Thorp
      Title: Chief Financial Officer
         
    Date: December 16, 2024    

     

    3/3

    Get the next $TCBP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TCBP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TCBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Randall Diana Elizabeth bought $350,000 worth of Ordinary Shares [ADS] (70,000 units at $5.00)

      4 - TC BioPharm (Holdings) plc (0001872812) (Issuer)

      1/11/23 4:29:05 PM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Randall Mark Edward bought $350,000 worth of Ordinary Shares [ADS] (70,000 units at $5.00) (Amendment)

      4/A - TC BioPharm (Holdings) plc (0001872812) (Issuer)

      1/11/23 4:09:21 PM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Randall Kenneth Edward bought $350,000 worth of Ordinary Shares [ADS] (70,000 units at $5.00) (Amendment)

      4/A - TC BioPharm (Holdings) plc (0001872812) (Issuer)

      1/11/23 3:59:36 PM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc

      SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

      11/14/24 4:41:42 PM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc (Amendment)

      SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

      2/14/24 2:34:04 PM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc (Amendment)

      SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

      1/29/24 9:16:48 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCBP
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $TCBP
    SEC Filings

    See more
    • TCBP Announces Transition from Nasdaq to OTC Markets

      EDINBURGH, Scotland, March 21, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company"), (NASDAQ:TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on March 20, 2025, it received notice that the Nasdaq Hearings Panel had determined to delist the Company's securities from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with Rule 5550(a)(2) of Nasdaq's Listing Rules. The Rule requires listed securities to maintain a minimum bid price of $1.00 per share. Management is currently working on an appeal with Nasdaq.

      3/21/25 10:45:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead

      The company is expected to reduce core operational burn by 55% when compared to 2024EDINBURGH, Scotland, March 18, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced initiatives to outsource several functions, moving to a more decentralized model, resulting in reduction in its workforce and creating a leaner and more agile organization as part of the company's strategic developmental plan. 

      3/18/25 8:03:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company

      FDA-approved product in a multi-billion-dollar marketRevenue generation projected in 2025EDINBURGH, Scotland, March 5, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a non-binding letter of intent to acquire a commercial-stage ophthalmic pharmaceutical company focused on commercializing novel therapies for decreasing intraocular pressure in patients with glaucoma and ocular hypertension.

      3/5/25 8:30:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by TC BioPharm (Holdings) plc

      6-K - TC BioPharm (Holdings) plc (0001872812) (Filer)

      3/21/25 11:22:27 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by TC BioPharm (Holdings) plc

      6-K - TC BioPharm (Holdings) plc (0001872812) (Filer)

      2/10/25 4:05:27 PM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by TC BioPharm (Holdings) plc

      6-K - TC BioPharm (Holdings) plc (0001872812) (Filer)

      1/8/25 4:16:27 PM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCBP
    Financials

    Live finance-specific insights

    See more
    • /C O R R E C T I O N -- TC BioPharm/

      In the news release, TCBP Issues 25% Stock Dividend, issued 30-Dec-2024 by TC BioPharm over PR Newswire, we are advised by the company that in the fourth paragraph, both instances of "January 8" should instead read "January 7". The complete, corrected release follows: TCBP Issues 25% Stock Dividend EDINBURGH, Scotland, Dec. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that shareholders have formally approved the recently announced 25% stock dividend.

      12/30/24 10:30:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TCBP Issues 25% Stock Dividend

      EDINBURGH, Scotland, Dec. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that shareholders have formally approved the recently announced 25% stock dividend. Today, TC BioPharm declared that last week's proposed special stock dividend was formally approved at today's General Meeting of the Company. The special dividend of 0.25 American Depositary Shares ("ADSs") for every 1 ADS he

      12/30/24 10:30:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TCBP Announces General Meeting of Shareholders to Approve One-Time Shareholder Dividend

      EDINBURGH, Scotland, Dec. 18, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its Board of Directors has approved a special dividend to its shareholders of 0.25 American Depositary Shares ("ADSs") for every 1 ADS held by shareholders, pending shareholder approval. The Company intends to hold a general meeting of shareholders ("GM") at 2:00 p.m. (UK time) on Monday, December 30, 2024, at The Seafield Arms Hotel, 17-19 Seafield St, Cullen, Buckie AB56 4SH, Scotland, United Kingdom.

      12/18/24 8:30:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCBP
    Leadership Updates

    Live Leadership Updates

    See more
    • TC BioPharm Announces Dr. Mike Leek as Chief Technology Officer

      EDINBURGH, Scotland, Feb. 23, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Dr. Michael Leek to the position of Chief Technology Officer. Dr. Leek resumes operational duties as CTO after stepping down as executive chairman of the board. With more than 35 years experience in cell-based research and development, Co-founder, Michael Leek, Ph.D., had previously served as TC BioPharm's Exec

      2/23/23 8:30:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TC BioPharm Announces New Chair of the Board, Arlene Morris

      EDINBURGH, Scotland, Feb. 14, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Arlene M. Morris to the position of Chair of the Board. Ms. Morris has held a seat on the TC BioPharm board as an independent director since 2022. An accomplished biotech executive and board member, with many years of experience, Ms. Morris has a proven track record of evolving businesses and en

      2/14/23 8:30:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TC BioPharm Announces Hiring of Chief Clinical Officer Bree Harlin to Lead Global Clinical Division

      Will oversee expansion of U.S. FDA Clinical TrialsEDINBURGH, Scotland, Jan. 30, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Bree Harlin as Chief Clinical Officer (CCO), effective immediately. Ms. Harlin brings more than twenty years of experience in research, oncology and clinical stage drug development to TC BioPharm.  Most recently she was with Loxo at Lilly, where

      1/30/23 8:30:00 AM ET
      $TCBP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care